Verenium Corporation
55 Cambridge Parkway
Cambridge,
MA 02142
United States - Map
Phone: 617-674-5300
Fax: 858-526-5551
Web Site: http://www.verenium.com
| Verenium Corporation engages in the development and production of specialty enzyme products, and production and commercialization of biofuels. It operates in two segments, Biofuels and Specialty Enzymes. The Biofuels segment focuses on the production and commercialization of biofuels, primarily ethanol from cellulosic biomass. The Specialty Enzymes segment develops enzymes for use in alternative fuels, specialty industrial processes, and animal nutrition and health markets. Its products include FuelzymeLF, an alpha amylase enzyme, designed to improve the efficiency and economics of ethanol production from corn and other grain, or starch sources; Purifine enzyme for biodiesel applications; Amylase-T Transgenic Corn Amylase; Purifine for edible nutritional oils; Luminase for pulp and paper processing; Phyzyme XP; Quantum phytase; Bayovac SRS that is designed to prevent disease in farmed Atlantic salmon; and Phytase-T, which supplements Quantum phytase. The company has strategic collaborations with Syngenta AG for the discovery and development of a range of novel enzymes; Bunge Oils, Inc. to discover and develop novel enzymes for the production of edible oil products; Cargill Health and Food Technologies to discover and develop novel enzymes for the production of a proprietary Cargill product; BASF AG to develop biocatalytic enzymes; Danisco Animal Nutrition to identify and develop a novel phytase enzyme; Bayer Animal Health to develop and market products to prevent infectious diseases in fish; and BP for the production of cellulosic ethanol from non-food feed stocks. It operates in North America, South America, Europe, Asia, and the Middle East. The company was formerly known as Diversa Corporation and changed its name to Verenium Corporation in June 2007 as a result of the merger with Celunol Corp. Verenium Corporation was founded in 1992 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Carlos Riva , 56
Chief Exec. Officer, Pres and Exec. Director |
$
703.00K |
$
0 | Mr. William Baum , 63
Exec. VP of Bus. Devel. and Gen. Mang. of Specialty Enzyme Bus. Unit |
$
467.00K |
$
0 | Mr. Jeffrey G. Black , 40
Chief Accounting Officer and Sr. VP |
$
436.00K |
$
0 | Mr. Gerald M. Haines II, 46
Chief Legal Officer, Exec. VP and Sec. |
$
370.00K |
$
0 | Mr. James E. Levine , 38
Chief Financial Officer and Exec. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 
0.22 (5.03%) 
Profile
